
Kairos Pharma, LTD.
94
Recent developments include positive interim clinical results for ENV 105 in prostate cancer, stock price volatility with a 52-week low, and multiple buy recommendations from analysts.
- Kairos Pharma reported interim progression-free survival benefit for ENV 105 in a Phase 2 prostate cancer trial, demonstrating clinical benefit in resistant patients [N1].
- The company’s stock hit a 52-week low amid market discussions of a reverse stock split and pipeline milestones [N2].
- D. Boral Capital maintained a buy recommendation on Kairos Pharma multiple times in late 2025 [N3][N4][N5][N6].
- HC Wainwright & Co. and Maxim Group initiated coverage with buy recommendations in early 2025 [N7][N8].
Kairos Pharma focuses on innovative cancer therapeutics designed to overcome immune suppression and drug resistance. Its pipeline includes five Kairos-developed immune-targeting drugs and two from its Enviro Therapeutics subsidiary. The lead drug ENV 105 targets endoglin to address resistance mechanisms in prostate and lung cancers, currently in clinical trials. Other candidates target immune checkpoints, tumor microenvironment, and chemotherapy resistance. The company operates virtually, leveraging academic partnerships for clinical trials.
Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company developing a diversified portfolio of seven drug candidates targeting cancer immune suppression and drug resistance. Its lead candidate, ENV 105, is in Phase 2 trials for prostate cancer and Phase 1 for lung cancer, showing clinical benefit in resistant patient populations. The company reported a net loss of $1.984 million and held $3.125 million in cash as of September 30, 2026, with strong liquidity ratios. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s diversified pipeline addresses significant unmet needs in oncology, including resistant prostate and lung cancers. Positive interim Phase 2 results for ENV 105 and NIH grant support for biomarker development enhance scientific validation. The novel small molecule approach for immune modulation and activated T cell therapies offer differentiated mechanisms. Strategic acquisitions and partnerships expand the pipeline and clinical reach.
Clinical-stage status entails inherent risks including trial failures, regulatory hurdles, and drug supply limitations. The company’s financial position shows net losses and limited cash reserves, necessitating capital raises. Market volatility and potential delisting risks due to share price pressures may impact liquidity and investor confidence. Companion diagnostics and biomarker approvals remain uncertain and could delay commercialization.
Kairos Pharma’s moat derives from its proprietary drug candidates targeting novel immune checkpoints and resistance mechanisms in cancer, supported by exclusive licenses from Cedars-Sinai Medical Center. Its diversified pipeline and companion biomarker development aim to improve patient selection and therapeutic efficacy. The company’s virtual operational model and collaborations with premier academic centers enhance clinical trial efficiency and capital deployment.
• Clinical Development Risk: The company’s drug candidates are in early clinical or preclinical stages with inherent risks of failure to demonstrate safety or efficacy.
• Regulatory Approval Risk: No product has received FDA or comparable foreign regulatory approval; companion diagnostics are also under development and not guaranteed approval.
• Financial Risk: The company reported net losses and holds limited cash, requiring effective capital management and potential financing to sustain operations.
• Market and Listing Risk: The company faces risks related to maintaining NYSE American listing standards, including minimum share price requirements that could lead to delisting.
• Operational Risk: Dependence on third-party clinical trial sites and virtual operational model may pose execution challenges.
Business trends: Advancement of multiple oncology drug candidates targeting immune suppression and resistance, with clinical trials underway for lead candidates.
Execution milestones: Completion of Phase 2 prostate cancer trial interim results, ongoing Phase 1 lung cancer trial, and companion biomarker development supported by NIH funding.
Key risks: Clinical and regulatory uncertainties, financial constraints, potential stock listing challenges, and operational dependencies on third-party clinical sites.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer patients targeting immune suppression and drug resistance [S1].
- The company’s portfolio includes seven drug candidates: five developed by Kairos targeting immune response (KROS 101, 102, 201, 301, 401) and two from its subsidiary Enviro Therapeutics, Inc. (ENV 105 and ENV 205) [S1].
- ENV 105 is in Phase 1 and Phase 2 clinical trials targeting prostate and lung cancers, addressing resistance to androgen targeted therapy and EGFR inhibitors [S1].
- A Phase 2 trial of ENV 105 in prostate cancer showed a clinical benefit rate of 62% in a heavily pre-treated, resistant patient population [S1].
- ENV 205 is a biologic targeting chemotherapy-resistant prostate cancers by depleting circulating mitochondrial DNA, currently preclinical [S1].
- KROS 101 is a small molecule GITR ligand antagonist in pre-IND studies aiming to modulate immune response with oral administration potential [S1].
- KROS 201 is an activated T cell therapy targeting glioblastoma, with IND-enabling studies completed [S1].
- Other pipeline candidates (KROS 102, 301, 401) are in preclinical development targeting immune modulation and tumor microenvironment [S1].
- The company operates virtually, leveraging partnerships with academic medical centers for clinical trials [S1].
- Financial snapshot as of 2026-09-30 shows cash and equivalents of $3.125 million, current assets of $3.35 million, current liabilities of $0.495 million, resulting in a current ratio of 6.77 and cash ratio of 6.31 [S2].
- Net loss for the period ending 2026-09-30 was $1.984 million with basic and diluted EPS of -$0.59 [S2].
- The company’s clinical trials include a Phase 2 prostate cancer trial with ENV 105 combined with standard hormone therapies, and a Phase 1 lung cancer trial [S1].
- A three-gene biomarker panel is under development as a companion diagnostic for ENV 105 to identify likely responders [S1].
- The NIH awarded a $3.2 million grant to support mechanism of action and biomarker development related to ENV 105 [S1].
- Recent news highlights include reporting interim progression-free survival benefit for ENV 105 in Phase 2 prostate cancer trial [N1].
- The company has experienced stock price volatility including a 52-week low amid discussions of reverse stock split and pipeline milestones [N2].
- Multiple buy recommendations from D. Boral Capital and coverage initiations by HC Wainwright and Maxim Group have been reported in 2025 [N3,N4,N5,N6,N7,N8].
Generated 2026-11-14
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-10-06 | www.nasdaq.com | Kairos Pharma Reports Interim PFS Benefit For ENV-105 In Phase 2 Prostate Cancer Trial | https://www.nasdaq.com/articles/kairos-pharma-reports-interim-pfs-benefit-env-105-phase-2-prostate-cancer-trial
- N2 | 2026-08-24 | www.nasdaq.com | Karios Pharma Hits 52-Week Low; Buzz Builds Around Reverse Split And Pipeline Milestone | https://www.nasdaq.com/articles/karios-pharma-hits-52-week-low-buzz-builds-around-reverse-split-and-pipeline-milestone
- N3 | 2025-11-19 | www.nasdaq.com | D. Boral Capital Maintains Kairos Pharma (KAPA) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-kairos-pharma-kapa-buy-recommendation-2
- N4 | 2025-11-05 | www.nasdaq.com | D. Boral Capital Maintains Kairos Pharma (KAPA) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-kairos-pharma-kapa-buy-recommendation-1
- N5 | 2025-10-20 | www.nasdaq.com | D. Boral Capital Maintains Kairos Pharma (KAPA) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-kairos-pharma-kapa-buy-recommendation-0
- N6 | 2025-10-08 | www.nasdaq.com | D. Boral Capital Maintains Kairos Pharma (KAPA) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-kairos-pharma-kapa-buy-recommendation
- N7 | 2025-08-27 | www.nasdaq.com | 5 Biotech Stocks To Watch Ahead Of Major Clinical Trial Data Readouts In September 2025 | https://www.nasdaq.com/articles/5-biotech-stocks-watch-ahead-major-clinical-trial-data-readouts-september-2025
- N8 | 2025-07-15 | www.nasdaq.com | Kairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105 | https://www.nasdaq.com/articles/kairos-pharma-stock-soars-after-positive-interim-results-phase-2-trial-env-105
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


